These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 1333201)
21. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662 [TBL] [Abstract][Full Text] [Related]
22. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. de Jong S; Zijlstra JG; de Vries EG; Mulder NH Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222 [TBL] [Abstract][Full Text] [Related]
23. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479 [TBL] [Abstract][Full Text] [Related]
24. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Kim D; Lee IS; Jung JH; Lee CO; Choi SU Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358 [TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines. Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500 [TBL] [Abstract][Full Text] [Related]
26. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130 [TBL] [Abstract][Full Text] [Related]
27. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha. McPherson JP; Deffie AM; Jones NR; Brown GA; Deuchars KL; Goldenberg GJ Anticancer Res; 1997; 17(6D):4243-52. PubMed ID: 9494516 [TBL] [Abstract][Full Text] [Related]
28. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines. Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741 [TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Jensen PB; Sehested M Biochem Pharmacol; 1997 Oct; 54(7):755-9. PubMed ID: 9353129 [TBL] [Abstract][Full Text] [Related]
30. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339 [TBL] [Abstract][Full Text] [Related]
31. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Harris LN; Yang L; Tang C; Yang D; Lupu R Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896 [TBL] [Abstract][Full Text] [Related]
32. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730 [TBL] [Abstract][Full Text] [Related]
33. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]. Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762 [TBL] [Abstract][Full Text] [Related]
34. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein. Satterwhite DJ; White RL; Matsunami N; Neufeld KL Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401 [TBL] [Abstract][Full Text] [Related]
36. [The effect of topoisomerase II inhibitor, vepesid, on binding of doxorubicin with DNA in tumor cells sensitive to anthracycline]. Bogush TA; Chmutin EF; Syrkin AB Biull Eksp Biol Med; 1997 Jan; 123(1):87-90. PubMed ID: 9213469 [No Abstract] [Full Text] [Related]
37. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765 [TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772 [TBL] [Abstract][Full Text] [Related]
39. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485 [TBL] [Abstract][Full Text] [Related]
40. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Lothstein L; Suttle DP; Roaten JB; Koseki Y; Israel M; Sweatman TW Biochem Pharmacol; 2000 Dec; 60(11):1621-8. PubMed ID: 11077044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]